Capmatinib in

Publication/Presentation Date

9-3-2020

Abstract

BACKGROUND: Among patients with non-small-cell lung cancer (NSCLC),

METHODS: We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with

RESULTS: A total of 364 patients were assigned to the cohorts. Among patients with NSCLC with a

CONCLUSIONS: Capmatinib showed substantial antitumor activity in patients with advanced NSCLC with a

Volume

383

Issue

10

First Page

944

Last Page

957

ISSN

1533-4406

Disciplines

Medicine and Health Sciences

PubMedID

32877583

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article

Share

COinS